Welcome to the InfoSci Platform
Overview of Nano-Strategies for Combating Cancer

Overview of Nano-Strategies for Combating Cancer

Yasodha Krishna Janapati, Sunil Junapudi, Sudharshan Reddy Dachani
Copyright: © 2021 |Pages: 21
ISBN13: 9781799850496|ISBN10: 1799850498|EISBN13: 9781799850502
DOI: 10.4018/978-1-7998-5049-6.ch012
Cite Chapter Cite Chapter

MLA

Janapati, Yasodha Krishna, et al. "Overview of Nano-Strategies for Combating Cancer." Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer, edited by Muthupandian Saravanan, et al., IGI Global, 2021, pp. 250-270. https://doi.org/10.4018/978-1-7998-5049-6.ch012

APA

Janapati, Y. K., Junapudi, S., & Dachani, S. R. (2021). Overview of Nano-Strategies for Combating Cancer. In M. Saravanan, V. Gopinath, & K. Deekonda (Eds.), Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer (pp. 250-270). IGI Global. https://doi.org/10.4018/978-1-7998-5049-6.ch012

Chicago

Janapati, Yasodha Krishna, Sunil Junapudi, and Sudharshan Reddy Dachani. "Overview of Nano-Strategies for Combating Cancer." In Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer, edited by Muthupandian Saravanan, Venkatraman Gopinath, and Karthik Deekonda, 250-270. Hershey, PA: IGI Global, 2021. https://doi.org/10.4018/978-1-7998-5049-6.ch012

Export Reference

Mendeley
Favorite

Abstract

Cancer is one of the prime rationales for mortality in humanity and remains a difficult disease to treat. Contemporary problems allied with conventional cancer chemotherapies embrace the insolubility of drugs in an aqueous medium, delivery of sub-therapeutic doses to target cells, lack of bioavailability, and most importantly, non-specific toxicity to normal tissues. Recent advances in nanotechnology investigation tackle potential solutions to these riddles. However, there are challenges regarding targeting specific sites, tracking the delivery system and control over the release of the drug to the target site. The nanodevices are 100 to 1000 times smaller than cells in humans; their size is comparable to the enzymes, the receptors. This enables them to have a large surface area and ability to interact with biomolecules on both the surface and inside cells. Nanomedicines between 8-100 nm have an enhanced permeability and retention (EPR) effect, which make these medicines to target passively the solid tumours.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.